What You Should Know:
– Lindus Health, a company transforming the clinical trial landscape with its tech-first approach raises $55M in Series B funding round led by Balderton Capital, with participation from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp.
– The funding will fuel the continued development of Lindus Health’s AI technology and eClinical platform, Citrus™, and support the company’s mission to make clinical trials faster, more reliable, and more affordable.
anti-CRO Model for Life Sciences
Clinical trials are essential for bringing new medical treatments to market, but the traditional process is notoriously slow, expensive, and inefficient. Contract research organizations (CROs), which manage these trials, often struggle to meet deadlines and budgets, with 85% of clinical trials experiencing delays. This sluggish pace hinders the development of life-saving therapies and drives up healthcare costs.
Lindus Health is disrupting the $112 billion CRO industry with its innovative “anti-CRO” model. By combining in-house technology with a vertically integrated approach to service delivery, Lindus Health is able to achieve significant efficiency gains and deliver faster, higher-quality clinical trials.
AI and Automation: The Keys to Transformation
Lindus Health’s proprietary clinical trial software platform, Citrus™, leverages the power of AI and automation to optimize every stage of the clinical trial process. This includes:
- Study design optimization: Predicting clinical trial outcomes from historical data using machine learning.
- Automated central monitoring: Streamlining data collection and analysis for improved oversight.
- Instant biostatistics: Generating real-time insights to inform decision-making.
- Efficient patient recruitment: Utilizing sophisticated methods to identify and enroll suitable participants.
Proven Track Record
Since its launch in 2021, Lindus Health has conducted 42 end-to-end clinical trials, enrolling over 36,000 patients across North America and Europe. The company has partnered with leading organizations like Aktiia and Pharmanovia on significant clinical research initiatives.
“The antiquated CRO model is failing the industry and failing patients, with inefficiencies and misaligned incentives propelling costs and causing researchers to stumble before their breakthroughs can reach patients,” said Meri Beckwith, co-founder of Lindus Health. “Lindus breaks the cycle by completely reinventing the way clinical trials operate, allowing life science companies to iterate faster.”
